Christopher Nixon Cox - 02 Jan 2026 Form 4 Insider Report for Alto Neuroscience, Inc. (ANRO)

Role
Director
Signature
/s/ Erin R. McQuade, Attorney-in-Fact
Issuer symbol
ANRO
Transactions as of
02 Jan 2026
Net transactions value
+$84,974
Form type
4
Filing time
06 Jan 2026, 16:47:14 UTC
Previous filing
15 May 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Cox Christopher Nixon Director C/O ALTO NEUROSCIENCE, INC., 650 CASTRO STREET, SUITE 450, MOUNTAIN VIEW /s/ Erin R. McQuade, Attorney-in-Fact 06 Jan 2026 0002008212

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ANRO Stock Option (right to buy) Award $84,974 +7,189 $11.82 7,189 02 Jan 2026 Common Stock 7,189 $16.59 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 1,797 shares underlying the option shall vest on March 31, 2026, 1,797 shares underlying the option shall vest on June 30, 2026, 1,798 shares underlying the option shall vest on September 30, 2026 and 1,797 shares underlying the option shall vest on December 31, 2026, subject to the Reporting Person's continuous service through each such vesting date.
F2 This option was issued to the Reporting Person pursuant to the Issuer's Non-Employee Director Compensation Policy in lieu of retainer fees of $85,000.